The Postprandial Effects of Chick-Pea Consumption on Glucose, Insulin, and Gut Hormone Responses (PEA-POD).

Launched by KING'S COLLEGE LONDON · Jun 20, 2019

Keywords

ClinConnect Summary

The nutritional and potential long-term health benefits of consuming pulses have been well documented. Pulses have a high fibre content, contribute to lowering fasting blood cholesterol levels and improving glycaemic control, and have shown also considerable promise in supporting the dietary management of cardiovascular disease (CVD), type-2 diabetes mellitus (T2DM) and obesity. They are gluten-free and are also an affordable and accessible source of starch, protein, and dietary fibre. It is now established that cellular integrity (maintenance of cell wall structure) is a key factor respons...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age: 18-45 y
• • Men and women
• • Healthy (free of diagnosed diseases listed in the exclusion criteria)
• • Body Mass Index 18-35 kg/m2
• • Able to understand the information sheet and willing to comply with study protocol
• • Able to give informed written consent
• Exclusion Criteria:
• • Those with known or suspected food allergies (particularly to wheat, as specified in the screening questionnaire and participant information form) or hypersensitivity
• • Women who are pregnant, intending to become pregnant, or breastfeeding
• • Participation in another clinical trial
• • Those who have donated blood within 3 months of the screening visit and participants for whom participation in this study would result in having donated more than 1500 millilitres of blood in the previous 12 months.
• • Body mass index \<18 or \>35 kg/m2
• • Full Blood Counts and Liver Function test results outside of the normal range.
• • Current smokers, or reported giving up smoking within the last 6 months History of substance abuse or alcoholism
• • Reported history of Cardiovascular disease, diabetes (or fasting glucose ≥ 7.1 mmol/L), cancer, kidney, liver or bowel disease, gastrointestinal disorder or use of drug likely to alter gastrointestinal function)
• • Blood pressure ≥160/100 mmHg
• • Total cholesterol ≥ 7.8 mmol/L; fasting triacylglycerol concentrations ≥ 5.0 mmol/L
• * Medications that may interfere with the study: alpha-glucosidase inhibitors (acarbose:
• • Glucobay), insulin- sensitising drugs (metformin: Glucophage, Glucophage SR, Eucreas, Janumet; thiazolidinediones: Actos, Competact), sulfonylureas (Daonil, Diamicron, Diamicron MR, Glibenese, Minodiab, Amaryl Tolbutamide), and lipid- lowering drugs (statins, nicotinic acid, colestyramine anhydrous, ezetimibe, fibrates).
• • Other medications should be reviewed by a medical representative from KCL on a case by case basis.